EXHIBIT 99.1

Akorn Provides Fourth Quarter and Full Year 2018 Results

LAKE FOREST, Ill., Feb. 28, 2019 (GLOBE NEWSWIRE) -- Akorn, Inc. (Nasdaq: AKRX), a leading specialty generic pharmaceutical company, today announced its financial results for the year ended 2018.


Fourth Quarter 2018 and Recent Business Highlights

  • Net revenue was $153 million, a decline of $33 million, or 17.6%, compared to the fourth quarter of 2017, predominantly due to the effect of competition on key products and shortfalls in supply
  • Net loss was $215 million compared to a net loss of $65 million in the fourth quarter of 2017.  Adjusted EBITDA was $(20) million compared to $28 million in the fourth quarter of 2017
  • Continued progress on completion of FDA action items related to the inspections of our facilities in Decatur and Somerset
  • Appointed Douglas Boothe as President and Chief Executive Officer, bringing significant generic and specialty pharmaceutical leadership experience
  • Announced new additions to Board of Directors and Executive Management team adding significant expertise to the Company’s leadership
  • Focused on moving forward and rebuilding shareholder value as an independent company following the terminated Fresenius Kabi AG merger agreement
  • Engaged financial, operational, and legal advisors to help develop and execute long-term growth plan
  • Healthy cash position of $225 million as of December 31, 2018

Douglas Boothe, Akorn’s President and Chief Executive Officer, commented, “I am excited to join Akorn at such a critical time for the Company.  Our recent financial results reflect the many challenges that have impacted our business of late, including increased competition for many of our generic and promoted products, supply issues, and regulatory and legal challenges.  Despite these significant headwinds, we have strong fundamentals to build upon, including a diverse product portfolio, a solid pipeline, niche manufacturing capabilities and, most importantly, a dedicated and extremely talented workforce.”

“During my first two months with Akorn, we have made structural and organizational changes to emphasize compliance, transparency, and accountability.  Additionally, we have decided to explore strategic alternatives to exit our India facility.  I believe these initial changes provide the foundational elements that will strengthen our business and enhance trust with our many stakeholders,” stated Boothe.  “I look forward to providing updates in the coming months on our go-forward strategy and plan to rebuild value for all of our stakeholders.”

Summary Financial Results for the Quarter Ended December 31, 2018:

Akorn reported revenues of $153.4 million for the three month period ended December 31, 2018, representing a decrease of $32.7 million, or 17.6%, as compared to net revenue of $186.1 million for the three month period ended December 31, 2017.  The decrease in net revenue in the period was primarily due to $32.6 million decline in organic revenue.  The $32.6 million decline in organic revenue was due to approximately $39.9 million, or 21.4% in volume declines partially offset by an increase of $7.3 million, or 3.9% in price.  The organic revenue decline was principally due to the effect of competition on Ephedrine Sulfate Injection, Nembutal Injection and Clobetasol Cream, and shortfalls in supply due to slower than expected resumption in manufacturing at our Decatur and Somerset manufacturing facilities after their extended planned shutdowns.

Gross profit for the quarter ended December 31, 2018 was $25.2 million, or 16.4% of net revenue, compared to $82.9 million, or 44.6% of net revenue, in the corresponding prior year quarter.  The decline in the gross profit percentage was principally due to: unfavorable variances related to decreased production at our Decatur and Somerset manufacturing facilities, increased operating costs associated with FDA compliance related improvement activities, as well as unfavorable product mix.

Net loss for the fourth quarter 2018 was $215.0 million, or $(1.71) per diluted share, compared to net loss of $65.2 million, or $(0.52) per diluted share, in the same quarter of 2017.  Including a net adjustment of $179.2 million to net income for non-GAAP items, adjusted diluted earnings per share for the fourth quarter 2018 were $(0.29), compared to $0.14 in the same quarter 2017, after a net adjustment of $82.4 million to net income for non-GAAP items.

Earnings before interest, taxes, depreciation and amortization (EBITDA) was $(174.1) million for the fourth quarter 2018, compared to $(98.4) million for the fourth quarter 2017.  Adjusted EBITDA, which is another non-GAAP measure used by management to evaluate the operations of the Akorn business, was $(19.9) million for the fourth quarter 2018, compared to $28.3 million for the fourth quarter 2017.  See “Non-GAAP Financial Measures” below.

Summary Financial Results for the Year Ended December 31, 2018:

Net revenue was $694.0 million for the twelve month period ended December 31, 2018, representing a decrease of $147.0 million, or 17.5%, as compared to net revenue of $841.0 million for the twelve month period ended December 31, 2017.  The decline was principally due to the effect of competition on Ephedrine Sulfate Injection, Nembutal, Lidocaine Ointment and Clobetasol Cream.  In addition, the Company experienced lower net revenue as a result of extended planned shutdowns at our Decatur and Somerset manufacturing facilities during the year.

Gross profit for the twelve month period ended December 31, 2018 was $246.0 million, or 35.4% of revenue, compared to $432.2 million, or 51.4% of revenue, for the twelve month period ended December 31, 2017.  The decline in the gross profit percentage was principally due to unfavorable product mix, unfavorable variances due to decreased production at our Decatur and Somerset manufacturing facilities, as well as increased operating costs associated with FDA compliance related improvement activities.

Net loss for 2018 was $401.9 million, or $(3.21) per diluted share, compared to net loss of $24.6 million, or $(0.20) per diluted share, for 2017.  Including a net adjustment of $378.2 million to net income for non-GAAP items, adjusted diluted earnings per share for 2018 were $(0.19), compared to $0.93 for 2017, after a net adjustment of $141.0 million to net income for non-GAAP items.

EBITDA was $(309.5) million for 2018, compared to $64.0 million for 2017.  Adjusted EBITDA was $49.3 million for 2018, compared to $245.5 million for 2017.  See “Non-GAAP Financial Measures” below.

Conference Call and Webcast Details:

As previously announced, Akorn’s management will hold a conference call with interested investors and analysts at 10:00 a.m. EST on February 28, 2019 to discuss these results and updates in more detail. The dial-in number to access the call is (844) 249-9382 in the U.S. and Canada and (270) 823-1530 for international callers. The conference ID is 4099919. To access the live webcast, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

A webcast replay of the conference call will be available shortly following the conclusion of the call and will be available for 90 days following the call. To access the webcast replay, please go to Akorn’s Investor Relations web site at http://investors.akorn.com.

About Akorn:

Akorn, Inc. is a specialty generic pharmaceutical company engaged in the development, manufacture and marketing of multisource and branded pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois; Somerset, New Jersey; Amityville, New York; Hettlingen, Switzerland and Paonta Sahib, India that manufacture ophthalmic, injectable and specialty sterile and non-sterile pharmaceuticals. Additional information is available on Akorn’s website at www.akorn.com.

Non-GAAP Financial Measures:

To supplement Akorn’s financial results presented in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses certain non-GAAP (also referred to as “adjusted” or “non-GAAP adjusted”) financial measures in this press release and the accompanying tables, including (1) EBITDA, (2) adjusted EBITDA, (3) adjusted net income, (4) adjusted diluted earnings per share, (5) net debt, and (6) net debt to adjusted EBITDA ratio. These non-GAAP measures adjust for certain specified items that are described in this release. The Company believes that each of these non-GAAP financial measures is helpful in understanding its past financial performance and potential future results. The non-GAAP financial measures are not meant to be considered in isolation or as a substitute for or superior to comparable GAAP measures.

Akorn’s management uses EBITDA, adjusted EBITDA, adjusted net income and adjusted diluted earnings per share in managing and analyzing its business and financial condition. Akorn’s management believes that the presentation of these and other non-GAAP financial measures provide investors greater transparency into Akorn’s ongoing results of operations allowing investors to better compare the Company’s results from period to period.

Investors should note that these non-GAAP financial measures used to present financial guidance are not prepared under any comprehensive set of accounting rules or principles and do not reflect all of the amounts associated with the Company’s results of operations as determined in accordance with GAAP. Investors should also note that these non-GAAP financial measures have no standardized meaning prescribed by GAAP and, therefore, have limits in their usefulness to investors. In addition, from time-to-time in the future there may be other items that the Company may exclude for purposes of its non-GAAP financial measures; likewise, the Company may in the future cease to exclude items that it has historically excluded for purposes of its non-GAAP financial measures. Because of the non-standardized definitions, the non-GAAP financial measures as used by Akorn in this press release and the accompanying tables may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by the Company’s competitors and other companies.

Set forth below is the definition of each non-GAAP financial measure as used by the Company in this press release and a full reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measures.

EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization.

Adjusted EBITDA, as defined by the Company, is calculated as follows:

Net (loss) income, (minus) plus:

  • Interest income (expense), net
  • Provision for income taxes
  • Depreciation and amortization
  • Non-cash expenses, such as impairment of long-lived assets, share-based compensation expense, and amortization of deferred financing costs
  • Other adjustments, such as legal settlements, restatement expenses and various merger and acquisition-related expenses, fixed asset impairment, executive termination payments, data integrity investigations & assessment, and Fresenius transaction & litigation

Adjusted EBITDA is deemed by the Company to be a useful performance indicator because it includes an add back of non-cash or non-recurring operating expenses that have no impact on continuing cash flows as well as other items that are not expected to recur and therefore are not reflective of continuing operating performance.

Adjusted net (loss) income, as defined by the Company, is calculated as follows:

Net (loss) income, (minus) plus:

  • Intangible asset amortization and impairment
  • Non-cash expenses, such as, share-based compensation expense, and amortization of financing costs
  • Other adjustments, such as legal settlements, restatement expenses and various merger and acquisition-related expenses, fixed asset impairment, executive termination payments, data integrity investigations & assessment, and Fresenius transaction & litigation
  • Less an estimated tax provision, net of the benefit from utilizing net operating loss carry-forwards effected for the adjustments noted above

Adjusted diluted earnings per share, as defined by the Company, is equal to adjusted net income divided by the actual or anticipated diluted share count for the applicable period. The Company believes that adjusted net income and adjusted diluted earnings per share are meaningful financial indicators, to both Company management and investors, in that they exclude non-cash income and expense items that have no impact on current or future cash flows, as well as other income and expense items that are not expected to recur and therefore are not reflective of continuing operating performance.

The shortcomings of non-GAAP financial measures as guidance or performance measures are that they provide a view of the Company’s results of operations without including all events during a period. For example, Adjusted EBITDA does not take into account the impact of capital expenditures on either the liquidity or the financial performance of the Company and likewise omits share-based compensation expenses, which may vary over time and may represent a material portion of overall compensation expense. Adjusted net income does not take into account non-cash expenses that reflect the amortization of past expenditures, or include share-based compensation, which is an important and material element of the Company's compensation package for its directors, officers and other key employees. Due to the inherent limitations of non-GAAP financial measures, investors should consider non-GAAP measures only as a supplement to, not as a substitute for or as a superior measure to, measures of financial performance prepared in accordance with GAAP. Investors and other readers are encouraged to review the related GAAP financial measures and the reconciliation of non-GAAP measures to their most directly comparable GAAP measures as presented in this press release.

Cautionary Note Regarding Forward-Looking Statements

This press release includes statements that may constitute "forward looking statements", including expectations regarding financial performance, rebuilding shareholder value, capital expenditures, growth, and other Akorn plans and strategy. When used in this document, the words “will,” “expect,” “continue," “believe,” “estimate,” “intend,” “could,” “strives” and similar expressions are generally intended to identify forward-looking statements. These statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. A number of important factors could cause actual results of Akorn and its subsidiaries to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to: (i) the effect of the Delaware court’s recent decision against Akorn on Akorn’s ability to retain and hire key personnel, its ability to maintain relationships with its customers, suppliers and others with whom it does business, or its operating results and business generally, (ii) the risk that ongoing or future litigation related to the court’s decision may result in significant costs of defense, indemnification and/or liability, (iii) the outcome of the investigation conducted by Akorn with the assistance of outside consultants, into alleged breaches of FDA data integrity requirements relating to product development at Akorn and any actions taken by Akorn, third parties or the FDA as a result of such investigations, (iv) the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any, (v) the timing and success of product launches, (vi) difficulties or delays in manufacturing, and (vii) such other risks and uncertainties outlined in the risk factors detailed in Part I, Item 1A, “Risk Factors,” of Akorn’s Annual Report on Form 10-K and other risk factors identified from time to time in our filings with the SEC. Readers should carefully review these risk factors, and should not place undue reliance on our forward-looking statements. These forward-looking statements are based on information, plans and estimates at the date of this report. Akorn undertakes no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes.

 
AKORN, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE (LOSS) INCOME
(In Thousands, Except Per Share Data)
 
 Three Months Ended
December 31,
 Year Ended
December 31,
 2018 2017 2018 2017
REVENUES$153,386  $186,057  $694,018  $841,045 
Cost of sales (exclusive of amortization of intangibles, included within
operating expenses below)
128,139  103,152  448,002  408,839 
GROSS PROFIT25,247  82,905  246,016  432,206 
Selling, general and administrative expenses69,778  61,356  279,628  216,324 
Acquisition-related costs22  38  121  159 
Research and development expenses10,867  10,592  47,321  44,988 
Amortization of intangibles13,487  15,152  53,472  61,443 
Impairment of intangible assets118,088  112,449  231,086  128,127 
Litigation rulings and settlements8,870  4,919  22,814  4,049 
TOTAL OPERATING EXPENSES221,112  204,506  634,442  455,090 
OPERATING (LOSS)(195,865) (121,601) (388,426) (22,884)
Amortization of deferred financing costs(1,304) (1,304) (5,216) (5,216)
Interest expense, net(13,569) (9,532) (45,900) (38,070)
Other non-operating income (expense), net1,378  3,100  1,360  6,972 
(LOSS) INCOME BEFORE INCOME TAXES(209,360) (129,337) (438,182) (59,198)
Income tax provision (benefit)5,678  (64,120) (36,273) (34,648)
NET (LOSS)$(215,038) $(65,217) $(401,909) $(24,550)
NET (LOSS) PER COMMON SHARE:       
NET (LOSS), BASIC$(1.71) $(0.52) $(3.21) $(0.20)
NET (LOSS), DILUTED$(1.71) $(0.52) $(3.21) $(0.20)
SHARES USED IN COMPUTING NET (LOSS) PER COMMON SHARE:       
BASIC125,492  125,083  125,383  124,790 
DILUTED125,492  125,083  125,383  124,790 
COMPREHENSIVE (LOSS):       
Net (loss)$(215,038) $(65,217) $(401,909) $(24,550)
Unrealized holding (loss) gain on available-for-sale securities, net of tax of $6 and ($157) for the years ended December 31, 2018 and 2017, respectively.(12)   (21) 267 
Foreign currency translation gain (loss) for the years ended December 31, 2018 and 2017, respectively.3,866  2,022  (8,001) 6,150 
Pension liability adjustment, net of tax of $389 and ($403) for the year ended December 31, 2018 and 2017, respectively.(1,541) 1,311  (1,529) 1,582 
COMPREHENSIVE (LOSS)$(212,725) $(61,884) $(411,460) $(16,551)
                


 
AKORN, INC.
CONSOLIDATED BALANCE SHEETS
(In Thousands,
Except Share Data)
 
 December 31,
 2018 2017
ASSETS   
CURRENT ASSETS   
Cash and cash equivalents$224,868  $368,119 
Trade accounts receivable, net153,126  141,383 
Inventories, net173,645  183,568 
Prepaid expenses and other current assets32,180  37,081 
TOTAL CURRENT ASSETS583,819  730,151 
PROPERTY, PLANT AND EQUIPMENT, NET334,853  313,418 
OTHER LONG-TERM ASSETS   
Goodwill283,879  285,310 
Intangible assets, net284,976  569,484 
Deferred tax assets  6,521 
Other non-current assets7,730  4,627 
TOTAL OTHER LONG-TERM ASSETS576,585  865,942 
TOTAL ASSETS$1,495,257  $1,909,511 
LIABILITIES AND SHAREHOLDERS’ EQUITY   
CURRENT LIABILITIES   
Trade accounts payable$39,570  $51,976 
Purchase consideration payable  3,901 
Income taxes payable  15,775 
Accrued royalties6,786  5,902 
Accrued compensation19,745  12,286 
Accrued administrative fees36,767  38,598 
Accrued legal fees and contingencies52,413  28,293 
Accrued expenses and other liabilities15,542  14,358 
TOTAL CURRENT LIABILITIES170,823  171,089 
LONG-TERM LIABILITIES   
Long-term debt (net of non-current deferred financing costs)820,411  815,195 
Deferred tax liability566  43,404 
FIN 48 reserve49,990  40,300 
Other long-term liabilities9,601  8,278 
TOTAL LONG-TERM LIABILITIES880,568  907,177 
TOTAL LIABILITIES1,051,391  1,078,266 
SHAREHOLDERS’ EQUITY   
Preferred stock, $1 par value —5,000,000 shares authorized; no shares issued or outstanding at December 31, 2018 and 2017   
Common stock, no par value — 150,000,000 shares authorized; 125,492,373 and 125,090,522 shares issued and outstanding at December 31, 2018 and 2017574,553  550,472 
(Accumulated deficit) Retained earnings(107,168) 294,741 
Accumulated other comprehensive loss(23,519) (13,968)
TOTAL SHAREHOLDERS’ EQUITY443,866  831,245 
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY$1,495,257  $1,909,511 
        


 
AKORN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In Thousands)
 
 Year ended December 31,
 2018 2017
OPERATING ACTIVITIES:   
Net (loss)$(401,909) $(24,550)
Depreciation and amortization82,805  85,173 
Impairment of intangible assets231,086  128,127 
Fixed asset impairment6,135   
Amortization of deferred financing fees5,216  5,216 
Non-cash stock compensation expense21,503  21,018 
Non-cash interest expense   
Income from available-for-sale securities  (3,032)
Deferred income taxes, net(37,396) (115,249)
Gain on sale of available-for-sale security  199 
Other421  (307)
Changes in operating assets and liabilities:   
Trade accounts receivable, net(11,627) 141,979 
Inventories, net9,694  (8,367)
Prepaid expenses and other current assets3,847  (12,232)
Other non-current assets(3,120) (3,519)
Trade accounts payable(5,002) (9,223)
Accrued legal fees and contingencies
24,120  21,492 
FIN48 Reserve9,690  38,999 
Accrued expenses and other liabilities(4,357) (18,091)
NET CASH (USED IN) PROVIDED BY OPERATING ACTIVITIES(68,894) 247,633 
INVESTING ACTIVITIES:   
Proceeds from disposal of assets30  4,815 
Payments for other intangible assets(50) (200)
Purchases of property, plant and equipment(69,111) (95,170)
NET CASH USED IN INVESTING ACTIVITIES(69,131) (90,555)
FINANCING ACTIVITIES:   
Proceeds under stock option and stock purchase plans546  9,320 
Stock compensation plan withholdings from employee taxes

(777) (1,726)
Payments of contingent acquisition liabilities(4,793)  
Lease Payments(14)  
NET CASH (USED IN) PROVIDED BY FINANCING ACTIVITIES(5,038) 7,594 
Effect of changes in exchange rates on cash and cash equivalents(1,032) 1,183 
 (DECREASE) INCREASE IN CASH AND CASH EQUIVALENTS(144,095) 165,855 
CASH AND CASH EQUIVALENTS, AND RESTRICTED CASH AT BEGINNING OF YEAR369,889  204,034 
CASH AND CASH EQUIVALENTS, AND RESTRICTED CASH AT END OF YEAR$225,794  $369,889 
        


 
AKORN, INC.
Reconciliation of GAAP Net (LOSS) to Non-GAAP EBITDA and Adjusted EBITDA
(In Thousands)
 
 Three Months Ended Year Ended
  December 31, December 31,
  2018 2017 2018 2017
NET (LOSS)$(215,038) $(65,217) $(401,909) $(24,550)
         
ADJUSTMENTS TO ARRIVE AT EBITDA:       
 Depreciation expense8,217  6,228  29,333  23,730 
 Amortization expense13,487  15,152  53,472  61,443 
 Interest expense, net13,569  9,532  45,900  38,070 
 Income tax provision (benefit)5,678  (64,120) (36,273) (34,648)
EBITDA$(174,087) $(98,425) $(309,477) $64,045 
         
NON-CASH AND OTHER NON-RECURRING INCOME AND EXPENSES       
 Data Integrity investigations & assessment6,021  514  28,420  514 
 Fresenius transaction & litigation8,303    43,305  7,354 
 Non-cash stock compensation expense4,304  5,392  21,503  21,018 
 Impairment of intangible assets118,088  112,449  231,086  128,127 
 Loss (Gain) from asset sales  3  (201) (2,802)
 Amortization of deferred financing costs1,304  1,304  5,216  5,216 
 Restatement expenses(273) 1,555  (1,018) 17,311 
 Executive termination payments6,455    6,455   
 Fixed asset impairment6,081  533  6,058  481 
 Litigation rulings and settlements3,870  4,919  17,814  4,049 
 Merger and Acquisition-related expenses22  38  121  159 
ADJUSTED EBITDA$(19,912) $28,282  $49,282  $245,472 
                

The table below sets forth expenses included in Net (loss) that have not been included as adjustments to arrive at EBITDA and Adjusted EBITDA in the preceding table.

   
  ($ in thousands)
 Three Months Ended Year Ended
  December 31, December 31,
  2018 2017 2018 2017
 FDA compliance related expenses12,517    22,251   
 Failure to supply penalties (recorded as a contra-revenue)7,462  4,446  22,453  18,231 
 TheraTears® direct-to-consumer advertising campaign6,219  13,118  17,393  14,070 
             


 
AKORN, INC.
Reconciliation of GAAP Net (Loss) to Non-GAAP Adjusted Net (Loss) Income and
Adjusted Diluted (Loss) Earnings Per Share
(In Thousands, Except Per Share Data)
 
 Three Months Ended Year Ended
 December 31, December 31,
 2018 2017 2018 2017
NET (LOSS)$(215,038) $(65,217) $(401,909) $(24,550)
Income tax provision (benefit)5,678  (64,120) (36,273) (34,648)
        
(LOSS) BEFORE INCOME TAXES$(209,360) $(129,337) $(438,182) $(59,198)
        
ADJUSTMENTS TO ARRIVE AT ADJUSTED NET (LOSS)
INCOME:
       
  Acquisition-related costs (1)22  38  121  159 
  Data Integrity investigations & assessment (2)6,021  514  28,420  514 
  Fresenius transaction & litigation (2, 9)8,303    43,305  7,354 
  Restatement expenses (2)(273) 1,555  (1,018) 17,311 
  Non-cash stock compensation expense (2, 3, 4)4,304  5,392  21,503  21,018 
  Amortization expense (5)13,487  15,152  53,472  61,443 
  Loss from asset sales (6)  3  (201) (2,802)
  Impairment of intangible assets (7)118,088  112,449  231,086  128,127 
  Amortization of deferred financing costs (8)1,304  1,304  5,216  5,216 
  Executive termination payments (2, 3)6,455    6,455   
  Fixed asset impairment (2)6,081  533  6,058  481 
  Litigation rulings and settlements (9)3,870  4,919  17,814  4,049 
        
ADJUSTED (LOSS) INCOME BEFORE INCOME TAX$(41,698) $12,522  $(25,951) $183,672 
        
Option exercise and RSU vesting tax impact (10)(332) 11,705  (2,748) 12,994 
ADJUSTMENTS TO INCOME TAX PROVISION (BENEFIT)(5,547) (16,403) 466  54,191 
TOTAL ADJUSTED INCOME TAX PROVISION (BENEFIT)$(5,879) $(4,698) $(2,282) $67,185 
        
ADJUSTED NET (LOSS) INCOME$(35,819) $17,220  $(23,669) $116,487 
        
ADJUSTED DILUTED (LOSS) EARNINGS PER SHARE (10)$(0.29) $0.14  $(0.19) $0.93 
        
(1) - Excluded from Acquisition-related costs 
(2) - Excluded from SG&A expenses 
(3) - Excluded from R&D expenses 
(4) - Excluded from Cost of sales 
(5) - Excluded from Amortization of intangibles 
(6) - Excluded from Other non-operating (expense) income, net 
(7) - Excluded from Impairment of intangible assets 
(8) - Excluded from Amortization of deferred financing costs 
(9) - Excluded from Litigation rulings and settlements 
(10) - Included in Income tax expense 
        


 
AKORN, INC.
Reconciliation of GAAP Debt to Non-GAAP Net Debt and Net Debt to Adjusted EBITDA Ratio
(In Thousands, Except Net Debt to Adjusted EBITDA Ratio)
 
 December 31, 2018
GAAP Debt$820,411 
Deferred financing costs11,527 
Total term loans outstanding$831,938 
Cash and cash equivalents224,868 
  Net debt (1)$607,070 
  
Adjusted EBITDA, year ended$49,282 
  
Net debt to adjusted EBITDA ratio (2)12.3 

(1) Net debt, as defined by the Company, is gross debt including Akorn’s term loan and revolving debt balances (if applicable) less cash and cash equivalents.

(2) Net debt to Adjusted EBITDA ratio, as defined by the Company, is net debt divided by the trailing twelve months Adjusted EBITDA.


Investors/Media:
(847) 279-6162
Investor.relations@akorn.com 


The following information was filed by Akorn Inc (AKRX) on Thursday, February 28, 2019 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.

View differences made from one year to another to evaluate Akorn Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Akorn Inc.

Continue

Never Miss A New SEC Filing Again


Real-Time SEC Filing Notifications
Screenshot taken from Gmail for a new 10-K Annual Report
Last10K.com Member Feature

Receive an e-mail as soon as a company files an Annual Report, Quarterly Report or has new 8-K corporate news.

Continue

We Highlighted This SEC Filing For You


SEC Filing Sentiment Analysis - Bullish, Bearish, Neutral
Screenshot taken from Wynn's 2018 10-K Annual Report
Last10K.com Member Feature

Read positive and negative remarks made by management in their entirety without having to find them in a 10-K/Q.

Continue

Widen Your SEC Filing Reading Experience


Increased Reading Area for SEC Filings
Screenshot taken from Adobe Inc.'s 10-Q Quarterly Report
Last10K.com Member Feature

Remove data columns and navigations in order to see much more filing content and tables in one view

Continue

Uncover Actionable Information Inside SEC Filings


SEC Filing Disclosures
Screenshot taken from Lumber Liquidators 10-K Annual Report
Last10K.com Member Feature

Read both hidden opportunities and early signs of potential problems without having to find them in a 10-K/Q

Continue

Adobe PDF, Microsoft Word and Excel Downloads


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshots of actual 10-K and 10-Q SEC Filings in PDF, Word and Excel formats
Last10K.com Member Feature

Export Annual and Quarterly Reports to Adobe PDF, Microsoft Word and Excel for offline viewing, annotations and analysis

Continue

FREE Financial Statements


Download Annual and Quarterly Reports as PDF, Word and Excel Documents
Screenshot of actual balance sheet from company 10-K Annual Report
Last10K.com Member Feature

Get one-click access to balance sheets, income, operations and cash flow statements without having to find them in Annual and Quarterly Reports

Continue for FREE

Intrinsic Value Calculator


Intrinsic Value Calculator
Screenshot of intrinsic value for AT&T (2019)
Last10K.com Member Feature

Our Intrinsic Value calculator estimates what an entire company is worth using up to 10 years of financial ratios to determine if a stock is overvalued or not

Continue

Financial Stability Report


Financial Stability Report
Screenshot of financial stability report for Coco-Cola (2019)
Last10K.com Member Feature

Our Financial Stability reports uses up to 10 years of financial ratios to determine the health of a company's EPS, Dividends, Book Value, Return on Equity, Current Ratio and Debt-to-Equity

Continue

Get a Better Picture of a Company's Performance


Financial Ratios
Available Financial Ratios
Last10K.com Member Feature

See how over 70 Growth, Profitability and Financial Ratios perform over 10 Years

Continue

Log in with your credentials

or    

Forgot your details?

Create Account